Cannabidiol (CBD) has been enjoying increasing amounts of attention as people learn more about its incredible possibilities as a supplement. With so many articles and research studies being written about CBD, you might think that this consumable is a recent discovery. It is true that many of the CBD extraction and packaging methods use cutting-edge technologies but the use of CBD in its hemp oil form goes back farther than most people realize.
Members of the MS community are more likely to experience symptoms of depression and anxiety, compared to individuals without MS. Worry and stress are common, and this type of emotional burden can take a toll on one’s health and relationships. Effective treatments as well as strategies to minimize the challenges are available. Please visit this section for more information.

   Industrial hemp has low THC levels compared to marijuana specifically cultivated for personal psychoactive use. Whereas marijuana that can be smoked usually contains between five and ten percent THC, industrial hemp contains about one-tenth of that. In order to get a psychoactive effect, one would need to smoke ten or twelve hemp cigarettes over a very short period of time. 

The most popular of them all at the moment is cannabidiol oil, or more commonly known as CBD oil. With so many new and different CBD oil products available, the choice of which one to go with can be difficult and confusing. With terms like whole plant extract, full spectrum, broad spectrum and isolate. This article will break down the difference between two terms you’ll commonly see, full spectrum CBD oil and CBD oil isolate, in order to help make your decisions easier.
CBD (short for cannabidiol) is one of at least 113 chemical compounds known as cannabinoids that are found in the cannabis plant. The popularity of CBD oil products continues to increase as more consumers learn about the potential health benefits. Anxiety, depression, chronic pain, inflammation and insomnia are just a few of the conditions cited by users who are successfully using CBD oil products.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
×